Esophageal squamous cell carcinoma (ESCC) is a severe health threat, being a predominant subtype of esophageal cancer and contributing significantly ...

While the use of CDK4/6 inhibitors combined with endocrine therapy ... PTEN loss, RTK-MAPK pathway alterations, RB1 loss, whole genome doubling, and high proportion of loss of heterozygosity.

Among the many promising advances in breast cancer treatment in recent years are CDK4/6 inhibitors. These are targeted drugs that can be used for women with a common type of breast cancer ...

The benefit was the same across subgroups, including among patients with visceral metastases, prior CDK4/6 therapy, or PI3K pathway mutation status. (1) “Imlunestrant as monotherapy or in combination ...

Dr. Yoshida's laboratory focuses on determining molecular mechanisms involved in the regulation of gene expression and signal transduction pathways in cancer development and drug resistance by using ...

including those with and without ESR1 mutations or PI3K-pathway mutations and including those previously treated with a CDK4/6 inhibitor. “The consistency of these results across clinically ...

Consistent benefits were observed across subgroups, including those with prior visceral metastases, CDK4/6 inhibitor therapy, and PI3K pathway mutations. In patients with prior CDK4/6 inhibitor ...

In this section, we will review several of the major co-opted pathways that represent additional tumor dependencies and signify equally tractable points of therapeutic intervention. MEK/CDK4 PD ...